Frontlight ResearchEarly access
Active, not recruitingNo phase
Long Term Follow-up After Primary or Revision Shoulder Arthroplasty With a Patient- Specific Glenius Implant
Key facts
- Who runs it
- Materialise
- Where
- Belgium and Netherlands4 sites in 2 countriesChoose a country to see its sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 24 people, planned
- Started
- 1 Jul 2019
- Expected to end
- Mar 2030
- Type of study
- Observational
- Treatments tested
- reversed glenoid prothesis
- Record updated
- 8 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 8 criteriaShow less
Who can take part
- patients having primary or revision shoulder joint replacement with severe glenoid bone defects
- Patient is 18 years of age or older
- Patient can follow the Glenius system procedure that is standard of care
- Patient is willing to cooperate in the required post-operative therapy
- Patient has participated in the informed consent process and has signed the EC approved informed consent form
Who cannot take part
- Pregnant patients
- Skeletally immature patients
- Prisoners
This trial has no sites in United States.
It has sites in 2 countries. Choose a country to see its sites.
About the trial
What the trial wants to find out
This post-market follow-up study investigates improvement in clinical and radiological outcome after reversed total shoulder arthroplasty with the patient-specific Glenius Glenoid Reconstruction system
The group in the trial
- Treatment group
Patients treated with a Glenius Glenoid Reconstruction System
Treatment: reversed glenoid prothesis
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Long Term Follow-up After Primary or Revision Shoulder Arthroplasty With a Patient- Specific Glenius Implant: A Prospective Cohort Study
- Record updated
- 8 October 2026